Analysts / Report Coverage

Paras Biopharmaceuticals in Analysts / Report Coverage
EinNewswires: Paras Biopharma Streamlines Offerings as “Biologics CDMO” and Biosimilar Co-Development as “Paras Biologics” December 2022
EinNewswires: Paras Biopharma Creates Excellence with Continuous Biomanufacturing -Achieves objectives of High Productivity Innovation. December 2022
PR.com/Benzinga: Paras Biopharmaceuticals is Highly Recommended for Biologics CDMO – Development, Scale-up & Production - November 2022
EinNewswires: Paras Biopharmaceuticals is Highly Recommended for Biologics CDMO – Development, Scale-up & Production - November 2022
EinNewswires: Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market worth $ 2.60 billion by 2030. Key players in this market includes Paras Biopharmaceuticals – September 2022
DelveInsight: Rich Insights into the Robust Osteoporosis Clinical Trials Pipeline Analysis. Key Osteoporosis companies include Paras Biopharmaceuticals. August 2022
Delveinsight: Key Osteoporosis companies such as Paras Biopharmaceuticals, and others, are evaluating new osteoporosis drugs candidate to improve the treatment landscape. August 2022
Nordic Life Science: “In Oulu, Finland, Paras Biopharmaceuticals has also started offering an expanded and increased biologics CDMO capacity to biopharmaceutical companies, beginning in March this year. 2022
BioSpace News Report: “In February 2019, Paras Biopharmaceuticals Finland Oy announced the successful development of biologically active Romiplostim.” Jun 13, 2022
Newswires News Report: “Paras Biopharmaceuticals Finland Oy – Exploring Reverse Merger Opportunity” May 03, 2022
Finance News Report: “Ranibizumab Biosimilars Market Research 2022: Comprehensive Insights About 17+ Companies and 17+ Marketed and Pipeline Drugs - ResearchAndMarkets.com” February 14, 2022
InsightAce Analytic: The Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market worth $ 635.9 million by 2028 - Exclusive Report where The prominent players in the Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing industry include Paras Biopharmaceuticals Finland. January 2022
Pr Newswire News Report: “The Live Biotherapeutic Products (LBP) And Microbiome Contract Manufacturing Market worth $ 635.9 million by 2028 - Exclusive Report by InsightAce Analytic” Jan 25, 2022
News Report: Named as “One of the Top Pharma Outsourcing Companies in Europe 2021”
Insulin Glargine Biosimilar Insight Report: 2020 Report Insulin Glargine Biosimilars Pipeline Drugs 2021”
News Report: Pipeline Review on Post-Menopausal Osteoporosis Metabolic Disorders pipeline landscape. 2021
InsightAce Analytic Pvt. Ltd: Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market Assessment 2021
Outlook India Magazine An Outlook Initiative with DigiLive Inspiring Business Leaders 2021
Biosimilar Insulin Market Research Report 2021 Elaborate Analysis with Growth Forecast To 2027. Top Companies in this report include Paras Biopharmaceuticals
Insulin biosimilar market 2021-2027: Growth analysis, CAGR status, market size, trends, growth prospects, types and in-depth qualitative insights. Leading manufacturers in the biosimilar insulin market including Paras Biopharmaceuticals Finland Oy
Global Postmenopausal Osteoporosis Market Nsights: Challenges and New Trends 2021 - Leading Players inc., Paras Biopharmaceutical Finland Oy
MarketInsights Reports Top Companies in the Global Biosimilar Insulin Market including Paras Biopharmaceuticals Finland Oy
2021 Biosimilar Insulin Sales Market Report- Recent Trends, Market Growth and Opportunities: Biosimilar Insulin Sales Market Research Report created by Report Consultant
Competitor Analysis Medical and Health Markets: Postmenopausal Osteoporosis Market 2021: Global industry analysis report to 2027
Competitor Analysis Biosimilar Insulin Market: Top vendors, upcoming trends, sales, revenue and profit margin, market size analysis to forecast period 2021-2027
Competitor Analysis: The Global Post Menopause Osteoporosis Market report features an in-depth analysis on the market development.
Data Bridge Market Research: Postmenopausal Osteoporosis Market to Register a Strong Growth Rate and Huge Profits, USA, 2021
Research Report: Biosimilar Insulin Market Prominent Growth by Clinical Aspect, Highlights and Key Developments, USA, 2021
Data Intelo Market Research: Biosimilar Insulin Market 2021 Will Reflect Significant Growth in Future with Size, Share, Growth, and Key Companies Analysis, USA, 2021
Competitor Analysis Report: Live Biotherapeutic Products and Microbiome Contract Manufacturing Market Growing Vigorously Among Top Key Players, USA, 2021
Competitor Analysis: Finland Advanced Facilities Analysis Market Informative Data: Trends, Challenges & Drivers 2021-2027, USA, 2021
Competitor Analysis: Global Biosimilar Insulin Market Segmentation, Growth Drivers, Market Size and Trends – 2021 – 2027, USA/UK, 2021
InsightAce Analytic: Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market Assessment – Industry Analysis, Clinical Trial/pipeline Analysis, COVID 19 Impact Analysis and Revenue Forecast Till 2028, India, 2020
News Report:Romiplostim Biosimilar to Begin Comparative Clinical Trials in 2019
Press Release: 2019 BIO International Convention Exhibitor, USA, 2019
Research and Markets - Osteoporosis/OA: Companies that are the most active within the pipeline for osteoporosis and OA therapeutics: Skeletal Disease Drug Development Pipeline Review 2017
Competitor Analysis:Paras Biopharmaceuticals to raise EUR 10m - EUR 20m with a view to mid-term IPO, MergerMarket, UK, 2014
Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies, Research and Markets, Ireland, 2014
Type 2 Diabetes:Pipeline Review, Global Market Direct, USA, 2014
Metastatic Prostate Cancer: Pipeline review, Research and Markets, Ireland, 2014
Post Menopausal Osteoporosis: Pipeline review, Global Market Direct, USA, 2014
Competitor Analysis Report: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors, Research and Markets, Ireland, 2013